Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article Report
  • Published:

Author’s response to “Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism”

Nature Clinical Practice Nephrology volume 3, page E1 (2007)Cite this article

Access through your institution
Buy or subscribe

Response to: Mansour J et al. (2007) Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. Nat Clin Pract Nephrol doi:10.1038/ncpneph0442

Original article: Bushinsky DA (2007) Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. Nat Clin Pract Nephrol 3: 12–13 doi:10.1038/ncpneph0363

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (4 Suppl 3): S1–S201

  2. Goodman WG (2004) Calcimimetic agents for the treatment of secondary hyperparathyroidism. Semin Nephrol 24: 460–463

    Article  CAS  Google Scholar 

  3. Gotch F et al. (2007) A kinetic model of calcium mass balance during dialysis therapy. Blood Purif 25: 139–149

    Article  CAS  Google Scholar 

  4. Coburn JW et al. (1973) Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264–272

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, 601 Elmwood Avenue, Box 675, Rochester, New York, NY 14642, USA david_bushinsky@urmc.rochester.edu

Authors and Affiliations

  1. University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, 601 Elmwood Avenue, Box 675, Rochester, New York, NY 14642, USA

    David A Bushinsky

Authors
  1. David A Bushinsky
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author has received grant support from the National Institutes of Health, the Renal Research Institute, Genzyme, Ilypsa and Amgen. He has been a member of advisory boards for Ilypsa, Amgen and Shire, and has been on speakers' bureaux for Amgen, Shire, Genzyme and the France Foundation. He owns stock in Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bushinsky, D. Author’s response to “Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism”. Nat Rev Nephrol 3, E1 (2007). https://doi.org/10.1038/ncpneph0449

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpneph0449

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing